BIO4WARD

ACIES BIO is a biotechnology contract research organization offering state-of-the-art R&D services to pharmaceutical, chemical, biotech and food industries. We provide full support from idea conceptualization through research to product development. Combining biotechnology and synthetic organic chemistry expertise, we offer a comprehensive service, covering all key development steps for efficient production of biosynthetic natural products or their semi-synthetic derivatives, as well as entirely synthetic compounds.

Working with some of the largest international companies, we provide to our clients full R&D support both in our laboratories as well as on-site at the client’s facilities.

With experience and know-how in natural product (bio)synthesis, milestone-based approach to projects, innovativeness and flexibility, as well as competitive pricing, ACIES BIO aims to become the premier partner in R&D outsourcing for pharmaceutical companies.

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.

Oroxcell is an independent research organization (CRO) offering research services assessing the safety, toxicity and efficacy of active ingredients and finished formulations.

Specialized in in-vitro testing, particularly in 3D Human Models, Oroxcell is developing its business on two fronts:

• Safety & efficacy testing: From screening to GLP Compliant studies, we provide well established In-vitro platform, 2D and 3D models, for performing routine and regulatory safety testing, ADME (Absorption, Distribution, Metabolism, and Elimination) and Toxicity (sensitization, phototoxicity and genotoxicity) tests, bioanalytical studies, for evaluating pharmaceuticals, medical devices, cosmetics, nutraceuticals, home care and chemical products.

• Research & Innovation: Oroxcell provides a wide range of services including R&D project management and technical support, international consortium setup and management and regulatory & toxicology consulting.
We assist you in selecting or developing the best alternative testing methods for your safety and efficacy issues.

Oroxcell has been certified GLP compliant (Grade A, the highest grade) since 2011 by the French National Medicines and Cosmetics Safety Agency, ANSM.


Website: http://www.oroxcell.com
Contact: contact@oroxcell.com

TGA BioServices, an Absorption Systems'​ Company, is an FDA inspected contract research laboratory providing the Pharmaceutical, Biotechnology and Research communities a comprehensive range of laboratory services in support of research and clinical studies. We offer the client a complete package of customized testing systems utilized in preclinical through Phase IV studies, all in compliance with cGLP and cGMP requirements.

We specialize in the development and validation of immunoassay systems for the detection of target molecules, antibody responses and quantification in total compliance with QA and cGMP standards.

TGA BioServices also offers in vivo mouse studies for the optimization of vaccine immunization schedules, dosing, adjuvant screening, immunogenicity testing for the release and stability of bulk and finished clinical product, as well as complete antibody development programs. Furthermore, we offer Guinea pig dermal sensitization testing for the identification of contact allergens. All programs are supervised by an in-house Institutional Animal Care and Use Committee (IACUC), while the facility is USDA registered and AAALAC accredited.

Other services provided include FACScan cell labeling studies, tissue culture, endotoxin testing, basic R&D activities, sample storage, specimen collection kits with on-site training, data management, protocol generation (SOP), database/statistical analysis and consultation. TGA BioServices has the credentials your project is searching for.

Our Mission
To create best niche antibody-based biologics for fulfilling the research and development needs in biomedical and biopharmaceutical communities. Our long range goal is to develop therapeutic and diagnostic entities.

Core Competence
ABB’s core competence is in protein designs of biologics for diagnostic and therapeutic applications of immuno-oncological disorders. Specifically, our R&D for therapeutics is focused on biologics that are capable of modulating activities associated with antigenic targets and effector molecules. In addition, ABB has designed and produced a panel of immune related protein reagents that are available to biomedical researchers as investigational tools.

History
Founded in 2007, AB Biosciences (ABB) has been dedicated to the engineering of therapeutic biologics and research protein reagents. With decades of combined experience in research and development, ABB’s scientists have built an efficient platform for the development of these two protein classes. The recombinant replacement of the traditional IVIG (PRIM program) is a great example of our engineering expertise in R&D of an unique protein drug for replacing the traditional serum-derived IVIG.

Our Community
Massachusetts provides a vibrant and nurturing environment for life science ventures like ABB, in terms of training grants and tax benefits, as well as an abundant talent pool possessing a wide range of expertise. Discovering breakthrough biotechnology and exploring biologics for biomedical study is our mission at AB Biosciences. As part of our commitment to science education, we open our doors to intern students, who can experience firsthand the R&D employment possibilities in the Biotech Industry. More than 15 students/interns have visited our laboratory since 2009.